Celularity PDA-002 achieves durable wound healing in diabetic foot ulcers.

Celularity's PDA-002, a regenerative therapy, achieved durable wound healing with just two intramuscular doses in diabetic foot ulcers complicated by peripheral artery disease. As a qualified stem cell therapy under Florida statute, PDA-002 may offer licensed Florida physicians a new tool in treating DFU patients, effective July 1, 2025. The therapy was tested in a Phase 2 multi-center, randomized, double-blind, placebo-controlled trial, according to StockTitan coverage.

Celularity Inc. (CELU), a clinical-stage biotechnology pioneer, has made significant strides in the treatment of diabetic foot ulcers (DFUs) complicated by peripheral artery disease (PAD). The therapy, derived from human placenta, showed promising results in the Phase 2 trial, indicating its potential to accelerate wound healing and improve patient outcomes. The trial's findings, published in a peer-reviewed journal, highlight the therapy's ability to promote epithelialization and reduce inflammation, key factors in DFU treatment; StockTitan coverage also discussed these results.

Celularity's progress in developing PDA-002 comes at a time when the company is also addressing financial challenges. The company has filed its Q1 and Q2 2025 Form 10-Q reports and regained compliance with Nasdaq Listing Rule 5250(c)(1). Additionally, Celularity has completed a major balance sheet restructuring, retiring all $41.6 million in senior secured debt. These financial maneuvers position the company to support the commercialization of its wound care products and late-stage 510(k) pipeline products.

The Florida Medical Association was actively involved in crafting the new legislation, which balances public protection and physician regulation. The law allows qualified physicians to administer investigational stem cell therapies for orthopedics, wound care, and pain management without FDA IND approval, provided the stem cells are sourced from FDA-registered facilities.

Celularity's FDA-registered facility in New Jersey is well-positioned to supply ethically sourced placenta-derived stem cells for these authorized therapies. The company, through its predecessor Anthrogenesis Corporation, pioneered the discovery of placental stem cell recovery methods in 2001, which was acknowledged by President George W. Bush.

With these advancements, Celularity is poised to expand its offerings and contribute to the broader field of regenerative medicine. As the company continues to navigate its financial landscape, investors and stakeholders should closely monitor Celularity's progress and the regulatory environment surrounding stem cell therapies.